Voyager Therapeutics Quick Ratio 2014-2022 | VYGR
Historical quick ratio values for Voyager Therapeutics (VYGR) over the last 10 years.
| Voyager Therapeutics Quick Ratio Historical Data |
| Date |
Current Assets - Inventory |
Current Liabilities |
Quick Ratio |
| 2022-03-31 |
$0.00B |
$0.10B |
0.00 |
| 2021-12-31 |
$0.00B |
$0.05B |
0.00 |
| 2021-09-30 |
$0.00B |
$0.03B |
0.00 |
| 2021-06-30 |
$0.00B |
$0.03B |
0.00 |
| 2021-03-31 |
$0.00B |
$0.03B |
0.00 |
| 2020-12-31 |
$0.00B |
$0.03B |
0.00 |
| 2020-09-30 |
$0.00B |
$0.04B |
0.00 |
| 2020-06-30 |
$0.00B |
$0.07B |
0.00 |
| 2020-03-31 |
$0.00B |
$0.07B |
0.00 |
| 2019-12-31 |
$0.00B |
$0.08B |
0.00 |
| 2019-09-30 |
$0.00B |
$0.08B |
0.00 |
| 2019-06-30 |
$0.00B |
$0.07B |
0.00 |
| 2019-03-31 |
$0.00B |
$0.06B |
0.00 |
| 2018-12-31 |
$0.00B |
$0.03B |
0.00 |
| 2018-09-30 |
$0.00B |
$0.03B |
0.00 |
| 2018-06-30 |
$0.00B |
$0.03B |
0.00 |
| 2018-03-31 |
$0.00B |
$0.03B |
0.00 |
| 2017-12-31 |
$0.00B |
$0.02B |
0.00 |
| 2017-09-30 |
$0.00B |
$0.02B |
0.00 |
| 2017-06-30 |
$0.00B |
$0.01B |
0.00 |
| 2017-03-31 |
$0.00B |
$0.01B |
0.00 |
| 2016-12-31 |
$0.00B |
$0.01B |
0.00 |
| 2016-09-30 |
$0.00B |
$0.02B |
0.00 |
| 2016-06-30 |
$0.00B |
$0.02B |
0.00 |
| 2016-03-31 |
$0.00B |
$0.02B |
0.00 |
| 2015-12-31 |
$0.00B |
$0.02B |
0.00 |
| 2015-09-30 |
$0.00B |
$0.02B |
0.00 |
| 2015-06-30 |
$0.00B |
|
0.00 |
| 2015-03-31 |
$0.00B |
|
0.00 |
| 2014-12-31 |
$0.00B |
$0.00B |
0.00 |
| 2014-09-30 |
$0.00B |
|
0.00 |
| 2014-06-30 |
$0.00B |
|
0.00 |
| 2014-03-31 |
$0.00B |
|
0.00 |
| 2013-12-31 |
$0.00B |
$0.00B |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.227B |
$0.037B |
|
Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.
|
